Analysts Set Coherus Oncology, Inc. (NASDAQ:CHRS) PT at $5.51

Shares of Coherus Oncology, Inc. (NASDAQ:CHRS) have been assigned a consensus rating of “Hold” from the five brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $5.5125.

CHRS has been the topic of a number of recent analyst reports. Oppenheimer began coverage on Coherus Oncology in a research note on Thursday, January 22nd. They set an “outperform” rating and a $10.00 price target on the stock. Wall Street Zen raised Coherus Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th.

Hedge Funds Weigh In On Coherus Oncology

A number of hedge funds have recently made changes to their positions in CHRS. Panagora Asset Management Inc. purchased a new position in shares of Coherus Oncology in the 2nd quarter worth about $581,000. International Assets Investment Management LLC acquired a new stake in Coherus Oncology during the 2nd quarter worth approximately $33,000. Tejara Capital Ltd raised its holdings in Coherus Oncology by 1.7% in the second quarter. Tejara Capital Ltd now owns 698,770 shares of the biotechnology company’s stock valued at $511,000 after buying an additional 11,552 shares during the period. ProShare Advisors LLC lifted its position in Coherus Oncology by 36.3% during the fourth quarter. ProShare Advisors LLC now owns 24,718 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 6,583 shares in the last quarter. Finally, Bronte Capital Management Pty Ltd. purchased a new stake in Coherus Oncology during the fourth quarter worth approximately $27,000. Institutional investors and hedge funds own 72.82% of the company’s stock.

Coherus Oncology Price Performance

NASDAQ:CHRS opened at $1.63 on Monday. Coherus Oncology has a 12-month low of $0.71 and a 12-month high of $2.62. The firm has a market cap of $197.02 million, a price-to-earnings ratio of 1.23 and a beta of 0.99. The company’s 50-day moving average is $1.69 and its two-hundred day moving average is $1.48. The company has a current ratio of 1.24, a quick ratio of 1.23 and a debt-to-equity ratio of 0.42.

Coherus Oncology Company Profile

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.